Biological E Partners With China's Recbio to Manufacture HPV9 Vaccine
Biological E. Limited (BE), a prominent vaccine producer in India, has formed a strategic licensing partnership with Jiangsu Recbio Technology Co Ltd to manufacture and market Recbio's 9-valent Human Papillomavirus (HPV9) vaccine, REC603, in India and selected international markets.
As part of the agreement, Recbio will transfer the necessary technology and provide the drug substance (DS) to BE, allowing the Indian company to formulate, fill, and package the vaccine.
Additionally, BE will obtain exclusive commercialization rights for India and will be eligible to participate in international tenders issued by UNICEF and the Pan American Health Organization (PAHO).
“This alliance reflects our mission to make essential vaccines accessible and affordable,” said Mahima Datla, Managing Director of BE.
“We are proud to bring this innovative HPV9 vaccine to India and global markets at a time when cervical cancer prevention is more urgent than ever.”
Also Read: Brands Empowering and Prioritizing the Ethical Handloom and Artisans
“This partnership marks a significant milestone for Recbio’s international expansion and for BE’s commitment to global health,” said Dr Liu Yong, Founder and CEO of Recbio.
“Together, we aim to accelerate the launch of this life-saving vaccine in India and beyond.”
The HPV9 vaccine, aimed at providing protection against nine types of HPV associated with cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts, is presently undergoing Phase III clinical trials in China. Cervical cancer continues to be the fourth most common cause of cancer-related fatalities among women worldwide, with HPV responsible for more than 690,000 cancer cases each year.
Also Read: 5 IIT Kharagpur Alumni Leading the Manufacturing Industry
BE, which provides vaccines to over 140 nations and possesses 10 WHO prequalified vaccines along with 10 USFDA-approved injectable products, will initiate large-scale production once the technology transfer is finalized. This partnership is anticipated to enhance the accessibility of cost-effective HPV prevention in lower- and middle-income countries.
The collaboration highlights the increasing international partnerships in vaccine development and production, particularly in response to the escalating worldwide need for cancer prevention options.